INCAGN02390

Phase 2Small molecule

Incyte

INCAGN02390 is one of 98 small molecule programs targeting Endometrial Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Endometrial CancerActive, not recruiting

Squamous Cell CarcinomaActive, not recruiting

Endometrial CancerPhase 2

Active, not recruiting

Squamous Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

103 competitors in Endometrial Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

53 2

Keytruda

Merck & Co.

Phase 3

21 3

Femara

Novartis

Phase 3

18 4

Paraplatin

AAvyxa

Phase 3

37 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

27 6

Megace

Bristol-Myers Squibb

Phase 3

10 7

Lenvima

Eisai

Phase 3

6 8

Lynparza

AstraZeneca

Phase 3

6 9

Depo-Provera

Eli Lilly

Phase 3

4 10

Tecentriq

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Endometrial Cancer1 trial

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

Active, not recruiting· Incyte logo

Incyte·Phase 2·NCT04463771·206 enrolled

Urothelial Carcinoma1 trial

An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

Terminated· Incyte logo

Incyte·Phase 2·NCT04586244·30 enrolled

Advanced Malignancies1 trial

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Completed· Incyte logo

Incyte·Phase 1·NCT03652077·40 enrolled

Squamous Cell Carcinoma1 trial

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting·IIncyte Biosciences International Sàrl·Phase 2·NCT05287113·176 enrolled

Melanoma1 trial

A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Completed· Incyte logo

Incyte·Preclinical·NCT04370704·61 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for INCAGN02390. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INCAGN02390 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INCAGN02390. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Incyte

INCAGN02390

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Endometrial Cancer1 trial

Urothelial Carcinoma1 trial

Advanced Malignancies1 trial

Squamous Cell Carcinoma1 trial

Melanoma1 trial

References

Drug Info

Quick Facts

Related News